Body Cream from South Korea

Product Details

Introducing Curicin PF Cream, a revolutionary 120-gram pain relief formulation developed as a natural, steroid-free alternative to conventional pain management solutions. This innovative product emerged from the dedicated research led by Dr. Shin Hyun-jong and a team of experts over five years, aiming to address the significant concerns associated with the use of narcotics, antibiotics, steroids, and their impact on human immunity and health.

Curicin PF Cream contains the natural microbiota compound OZL-M100, a result of meticulous research and development. OZL-M100 is at the forefront of natural medicine, bioactive materials, and medical cosmetics, offering a side-effect-free solution to pain management. This compound embodies the core values of natural healing, providing a biologically active material essential for today's healthcare.

The development of Curicin PF Cream was driven by the urgent need for safer pain management alternatives. Congressional testimonies and surveys, including those from the American Society of Interventional Pain Physicians (ASIPP), highlight the alarming consumption rates and dependency issues associated with opioid painkillers in the United States. Curicin PF aims to offer an effective, non-opioid, and non-steroidal option to combat pain, addressing the considerable market demand for integrative, complementary, or alternative treatments for chronic pain, neuropathic pain, fibromyalgia, and bone/arthritis pain.

Curicin PF Cream, recognized globally for its innovative approach, has obtained quasi-drug status from the U.S. FDA, marking a significant milestone as the world's first in this category. The cream is part of a broader range of pain management solutions, including NEURO cosmetics, oral treatments, and injectables, designed to address various bacterial dermatitis and somatic pain treatments.

The formulation leverages NEURO TECHNOLOGY to control cell activity and alleviate pain through neurotransmitter movement between nerve cells and skin cells. It utilizes ultra-low molecule technology for enhanced absorption and fermentation and bio-conversion technology to produce a microbiota natural product-derived compound (OZL-M100).

Curicin PF Cream is effective against somatic pain, bacterial dermatitis, and inflammatory pain, showcasing the analgesic and anti-inflammatory properties of its natural ingredients. It represents a significant achievement for the company, achieving sales of 50 million dollars (USD) by 2023 and becoming a brand exported to a major French pharmacy chain.

Curicin PF Cream is not just a product but a testament to the potential of natural, non-opioid, and steroid-free pain relief solutions. It stands as a beacon of hope for millions seeking alternative treatments free from the side effects and dependency risks associated with conventional painkillers.

Highlights;

• Development Background:
  • Aimed to find a natural substitute for steroids due to the adverse effects of chemicals, narcotics, antibiotics, and steroids on human immunity.
  • Dr. Shin Hyun-jong and a team conducted five years of research to develop a natural microbiota compound, OZL-M100, as a steroid alternative.
• Innovative Compound:
  • OZL-M100 is a natural, bioactive material that serves as the core of natural medicines, bioactive materials, and medical cosmetics without side effects.
• Market Need:
  • Addressing the high consumption of opioids in the US, with Americans consuming 80% of the world's painkillers leading to addiction and other serious side effects.
  • The demand for non-opioid, steroid-free, and side-effect-free pain management solutions.
• Product Description:
  • Curicin PF Cream is a 120-gram pain relief drug developed as a new concept without steroid ingredients.
  • It has received NDC status from the U.S. FDA, making it the first quasi-drug of its kind globally.
• Technology and Patents:
  • Features NEURO TECHNOLOGY for pain relief through neurotransmitter movement.
  • Utilizes ultra-low molecule technology for increased absorption of its active ingredients.
  • Fermentation and bio-conversion technology used to develop the microbiota natural product-derived compound (OZL-M100).
    
• Certifications and Applications:
  • FDA registered as a quasi-drug with functional certification.
  • Applicable for treating various bacterial dermatitis and somatic pain treatments.
    
• Market Impact:
  • Achieved sales of 50 million dollars (USD) by 2023.
  • Exported as a brand to a major French pharmacy chain.

Curicin PF Cream represents a significant advancement in the field of pain management, offering a natural, effective solution for those seeking alternatives to traditional pain relief methods.